Thyrocare Technologies Q1 Review - Base Business Weak; Covid-19 Tests Helped: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Thyrocare Technologies Ltd. reported largely in-line revenue but higher, margins aided by reduction in costs.
Excluding Covid-19 revenue grew at two-year compound annual growth rate of 4.4%, with volumes declining 8.3%.
RT-PCR and anti-body tests contributed 30.6% of total revenue.
Total revenue grew 193% YoY to Rs 1.6 billion (our estimate: Rs 1.6 billion) on a very low base.
Ebitda margin improved 820 basis points QoQ to 43.3% (our estimate: 36.5%) due to significant reduction in selling, general and administrative and staff expenses.
PharmEasy had recently announced to acquire Thyrocare which may help in improving volumes over long term.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.